Marc DiSabella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Marc DiSabella has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Jeffrey Strelzik
Division of Neurology, The George Washington University/Children's National Hospital, Washington, DC, USA
3 shared publications - Mrinmayee Takle
Division of Neurology, The George Washington University/Children's National Hospital, Washington, DC, USA
3 shared publications - Raquel Langdon
George Washington University School of Medicine, Children’s National Hospital, Washington, DC, USA
3 shared publications - Elizabeth Pickup
Children's National Hospital
2 shared publications Emily McCracken
2 shared publications- Emily McCracken
Children’s National Hospital, Washington, DC, USA
2 shared publications
Latest Publications
- 17 October 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 186, 26-30
Peripheral Nerve Blocks in the Treatment of Pediatric Headaches
- 17 October 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 186, 26-30
Peripheral Nerve Blocks in the Treatment of Pediatric Headaches
- 9 July 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 183, 85-91
Onabotulinumtoxin A is an effective preventative treatment of chronic and daily pediatric migraine
- 9 July 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 183, 85-91
Onabotulinumtoxin A is an effective preventative treatment of chronic and daily pediatric migraine
- 1 September 2025
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 41 (9) , 1277-1282
Coenzyme Q10 Supplementation May Be Correlated With Resolution of New Daily Persistent Headache
New daily persistent headache is a chronic, treatment-resistant primary headache disorder with limited guidance on effective management. Despite its significant impact on headache-related quality of life, few studies have identified targeted therapies that contribute to symptom resolution. This study aims to describe the outcomes of pediatric patients diagnosed with new daily persistent headache and assess associations between specific interventions and headache resolution. A retrospective review was conducted using data from a patient registry at Children's National Hospital. Patients diagnosed with new daily persistent headache were included. Demographic characteristics, clinical features, prior treatments, and resolution rates were analyzed. Statistical comparisons were made between patients who experienced headache resolution and those with persistence of headache. A total of 182 pediatric patients were included (mean age: 15.5 years; 78% female). Headache resolution occurred in 47 patients (25.8%). For patients whose new daily persistent headache resolved, coenzyme Q10 (CoQ10) supplementation was the only treatment that reached statistical significance, being more frequently administered in the resolved group compared with the nonresolved group (17% vs 4%, P = .010). Additional treatments approaching statistical significance during resolution of new daily persistent headache included magnesium ( P = .086), topiramate ( P = .112), and onabotulinum toxin A injections ( P = .179). Patients who engaged in regular exercise showed a trend toward higher resolution rates ( P = .058). CoQ10 supplementation may play a role in new daily persistent headache resolution, with potential benefit from exercise, magnesium, topiramate, and onabotulinum toxin A injections approaching significance. Further prospective studies and randomized controlled trials are needed to establish causality and optimize treatment strategies for pediatric new daily persistent headache.
- 1 September 2025
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 41 (9) , 1277-1282
Coenzyme Q10 Supplementation May Be Correlated With Resolution of New Daily Persistent Headache
New daily persistent headache is a chronic, treatment-resistant primary headache disorder with limited guidance on effective management. Despite its significant impact on headache-related quality of life, few studies have identified targeted therapies that contribute to symptom resolution. This study aims to describe the outcomes of pediatric patients diagnosed with new daily persistent headache and assess associations between specific interventions and headache resolution. A retrospective review was conducted using data from a patient registry at Children's National Hospital. Patients diagnosed with new daily persistent headache were included. Demographic characteristics, clinical features, prior treatments, and resolution rates were analyzed. Statistical comparisons were made between patients who experienced headache resolution and those with persistence of headache. A total of 182 pediatric patients were included (mean age: 15.5 years; 78% female). Headache resolution occurred in 47 patients (25.8%). For patients whose new daily persistent headache resolved, coenzyme Q10 (CoQ10) supplementation was the only treatment that reached statistical significance, being more frequently administered in the resolved group compared with the nonresolved group (17% vs 4%, P = .010). Additional treatments approaching statistical significance during resolution of new daily persistent headache included magnesium ( P = .086), topiramate ( P = .112), and onabotulinum toxin A injections ( P = .179). Patients who engaged in regular exercise showed a trend toward higher resolution rates ( P = .058). CoQ10 supplementation may play a role in new daily persistent headache resolution, with potential benefit from exercise, magnesium, topiramate, and onabotulinum toxin A injections approaching significance. Further prospective studies and randomized controlled trials are needed to establish causality and optimize treatment strategies for pediatric new daily persistent headache.
- Open Access
- 24 August 2022
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 37 (10-11) , 871-881
Pediatric Headache Experience During the COVID-19 Pandemic
Objective: Headache disorders are exceedingly common in children and adolescents. The association between headaches, emotional stress, and disruptions in daily routines are well established. The goal of this study is to compare the experiences of patients with a preexisting diagnosis of a primary headache disorder in terms of headache frequency and severity, lifestyle techniques for headache prevention, screen use, and mood from before and after the onset of the COVID-19 pandemic. Methods: Patients evaluated by the Headache Clinic at Children’s National Hospital between Summer 2020 and Winter 2021 were enrolled in a patient registry. Patients completed a questionnaire examining changes in headache characteristics and lifestyle factors since the onset of the COVID-19 pandemic. Results: A total of 107 patients completed the survey. Since the pandemic’s onset, patients reported decreased physical activity (n = 59, 55%), increased frequency of chronic headaches from 40% (N = 42) to 50% (N = 54), and increased constant daily headaches from 22% (n = 24) to 36% (n = 38). Patients reported worsened anxiety (n = 58, 54%), mood (n = 50, 47%), and workload (n = 49, 46%). Sixty-one percent (n = 65) of patients reported using screens for school for more than 6 hours per day. The majority (n = 67, 63%) of patients indicated that they would prefer attending in-person school, with 14% (n = 15) responding that they preferred online school. Conclusion: Since the COVID-19 pandemic’s onset, pediatric headache patients have experienced increasing headache frequency, worsening anxiety and mood, decreased physical activity, and increased screen usage. Although this study is limited by sample size and observational design, future population-based studies will further elucidate the impact of this pandemic on pediatric headache.
- 24 August 2022
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 37 (10-11) , 871-881
Open AccessPediatric Headache Experience During the COVID-19 Pandemic
Objective: Headache disorders are exceedingly common in children and adolescents. The association between headaches, emotional stress, and disruptions in daily routines are well established. The goal of this study is to compare the experiences of patients with a preexisting diagnosis of a primary headache disorder in terms of headache frequency and severity, lifestyle techniques for headache prevention, screen use, and mood from before and after the onset of the COVID-19 pandemic. Methods: Patients evaluated by the Headache Clinic at Children’s National Hospital between Summer 2020 and Winter 2021 were enrolled in a patient registry. Patients completed a questionnaire examining changes in headache characteristics and lifestyle factors since the onset of the COVID-19 pandemic. Results: A total of 107 patients completed the survey. Since the pandemic’s onset, patients reported decreased physical activity (n = 59, 55%), increased frequency of chronic headaches from 40% (N = 42) to 50% (N = 54), and increased constant daily headaches from 22% (n = 24) to 36% (n = 38). Patients reported worsened anxiety (n = 58, 54%), mood (n = 50, 47%), and workload (n = 49, 46%). Sixty-one percent (n = 65) of patients reported using screens for school for more than 6 hours per day. The majority (n = 67, 63%) of patients indicated that they would prefer attending in-person school, with 14% (n = 15) responding that they preferred online school. Conclusion: Since the COVID-19 pandemic’s onset, pediatric headache patients have experienced increasing headache frequency, worsening anxiety and mood, decreased physical activity, and increased screen usage. Although this study is limited by sample size and observational design, future population-based studies will further elucidate the impact of this pandemic on pediatric headache.